ClinicalTrials.Veeva

Menu

A Post-Market Clinical Follow-up Study in Patients Treated With Vascular Grafts (FLOWGRAFT)

J

JOTEC

Status

Enrolling

Conditions

Vascular Diseases

Treatments

Device: Open repair

Study type

Observational

Funder types

Industry

Identifiers

NCT05145517
FLOWGRAFT

Details and patient eligibility

About

The FLOWGRAFT post-market clinical follow-up study is undertaken to show the safety and performance of FlowWeave Bioseal, FlowNit Bioseal, FlowLine Bipore and FlowLine Bipore Heparin (combined named as Vascular Grafts) in the treatment of arterial diseases, such as dissection, aneurysm, intramural hematoma (IMH), penetrating aortic ulcer (PAU), contained rupture, stenosis in the aorta or peripheral arteries (lower limbs). This includes the use of FlowWeave Bioseal or FlowNit Bioseal for debranching of the head vessels in an alone standing procedure. Furthermore, it includes the use of the FlowLine Bipore and FlowLine Bipore Heparin Grafts as arterious-venous (AV) shunt.

Full description

In this study, patients who receive a Vascular Graft for the treatment of arterial diseases (aneurysm, PAU, IMH, dissection, stenosis) of the aorta or peripheral arteries (lower limbs) or as an AV shunt will be observed. This includes patients in whom the Vascular Grafts are used for debranching or reconstruction of the head vessels. Participating physicians will be asked to provide the observations, that were collected during routine care. Written informed consent, specifically allowing the use of clinical records for this observational study, will be obtained from every patient prior to data collection.

The period of data collection will be approximately 60 + 6 months (depending on the date of the last follow-up visit) from the date of intervention for each patient.

Enrollment

500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient ≥ 18 years at time of written informed consent

  • Patient was selected for treatment with a commercially available Vascular Graft of JOTEC

  • Patient satisfies at least one of the following categories:

    • Acute (14 days) / subacute (15 - 90 days) dissection with double lumina in the aorta or peripheral artery / arteries (lower limb)
    • Chronic (>90 days) dissection with double lumina in the aorta or peripheral artery / arteries (lower limb)
    • Aneurysm in the aorta or peripheral artery / arteries (lower limb)
    • IMH in the aorta or peripheral artery / arteries (lower limb)
    • PAU in the aorta or peripheral artery / arteries (lower limb)
    • Contained rupture in the aorta or peripheral artery / arteries (lower limb)
    • Stenosis in the aorta or peripheral artery / arteries (lower limb)
    • Debranching of head vessels
    • AV shunt
  • Patient is willing and able to comply with all clinical study procedures and study visits.

  • Patient has given written informed consent to participate in the study.

Exclusion criteria

  • Patient has any other medical, social, or psychological problem that in the opinion of the investigator preclude them from receiving this treatment, procedures, and evaluations pre- and post-procedure.
  • Patient is scheduled for reconstruction of the tibial artery

Trial contacts and locations

1

Loading...

Central trial contact

Heike Fischer, Dr.; Alexander Oberhuber, Prof. Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems